Help paying · Medicare negotiated price · pharmacy cost · cycle 2026
Novolog (insulin aspart, human): where help paying exists, what Medicare negotiated and what pharmacies pay
2 assistance programs list insulin aspart, human, each with its income ceiling and when we read it. Medicare's negotiated price for a 30-day supply is $119 (in force since January 1, 2026). CMS's file lists all 17 packages of Novolog as deselected from the negotiation program, with the negotiated price ending December 31, 2026. After that date there is no negotiated price for them. The file does not say why. Per unit, the negotiated price is 100% of NADAC, the pharmacy acquisition benchmark. The FDA's enforcement reports name this drug's packages in 5 recall entries. ClinicalTrials.gov lists 8 recruiting trials that name insulin aspart, human.
One package, side by side
Price per unit for one package of Novolog. The negotiated price applies to Medicare Part D; NADAC is a survey of what retail pharmacies pay to buy the drug.
Swipe to read across
Every package we can price
Per-unit prices (per mL, as the files state). "Scheduled" is a price the CMS file already dates for the future.
| NDC | Product | Unit | Negotiated now | Scheduled | NADAC | Share |
|---|---|---|---|---|---|---|
| 00169-2100-11 | NOVOLOG 10ML RELION | n/a | $6.96 | ends 2026-12-31 | n/a | no NADAC price |
| 00169-2101-12 | NOVOLOG FP 3ML RELION INNER | n/a | $8.96 | ends 2026-12-31 | n/a | no NADAC price |
| 00169-2101-25 | NOVOLOG FP 5X3ML RELION | n/a | $8.96 | ends 2026-12-31 | n/a | no NADAC price |
| 00169-3201-11 | FIASP VIAL 10 ML | ML | $6.96 | ends 2026-12-31 | $6.92 | 101% |
| 00169-3204-15 | FIASP FLEXTOUCH 5X3 ML | ML | $8.96 | ends 2026-12-31 | $8.91 | 101% |
| 00169-3205-11 | FIASP PENFILL 100U/ML 5X3ML INNER | n/a | $8.61 | ends 2026-12-31 | n/a | no NADAC price |
| 00169-3205-15 | FIASP PENFILL 100U/ML 5X3ML | ML | $8.61 | ends 2026-12-31 | $8.54 | 101% |
| 00169-3206-11 | FIASP PUMPCART 100U/ML 1X1.6ML INNER | n/a | $6.96 | ends 2026-12-31 | n/a | no NADAC price |
| 00169-3206-15 | FIASP PUMPCART 100U/ML 5X1.6ML | ML | $6.96 | ends 2026-12-31 | $8.57 | 81% |
| 00169-3303-12 | NOVOLOG PENFILL 3 ML | ML | $8.61 | ends 2026-12-31 | $8.57 | 100% |
| 00169-6339-10 | NOVOLOG FLEXPEN 5X3ML | ML | $8.96 | ends 2026-12-31 | $8.93 | 100% |
| 00169-7501-11 | NOVOLOG 10 ML | ML | $6.96 | ends 2026-12-31 | $6.93 | 100% |
| 73070-0100-11 | INSULIN ASPART 10ML VIAL | ML | $3.48 | ends 2026-12-31 | $6.95 | generic, not compared |
| 73070-0102-10 | INSULIN ASPART PENFILL 3ML - INNER | n/a | $4.31 | ends 2026-12-31 | n/a | no NADAC price |
| 73070-0102-15 | INSULIN ASPART PENFILL 5 X 3ML | ML | $4.31 | ends 2026-12-31 | $8.57 | generic, not compared |
| 73070-0103-10 | INSULIN ASPART FLEXPEN 3ML - INNER | n/a | $4.48 | ends 2026-12-31 | n/a | no NADAC price |
| 73070-0103-15 | INSULIN ASPART FLEXPEN 5X3ML | ML | $4.48 | ends 2026-12-31 | $8.96 | generic, not compared |
Medicare Part D spending
CMS's Medicare Part D spending dataset reports gross spending on Novolog of $318.91 million in 2024, across 1,483,591 claims and 479,549 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
| Year | Gross spending | Claims | Beneficiaries | Average spending per claim |
|---|---|---|---|---|
| 2024 | $318.91 million | 1,483,591 | 479,549 | $215 |
| 2023 | $1.88 billion | 2,118,734 | 588,526 | $885 |
| 2022 | $1.84 billion | 2,088,291 | 567,315 | $881 |
| 2021 | $1.82 billion | 2,114,717 | 566,994 | $860 |
| 2020 | $1.84 billion | 2,265,569 | 585,300 | $814 |
Source: CMS Medicare Part D spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. All manufacturers combined; the figures are a drug-level aggregate of claims and say nothing about a formulary or coverage.
Medicare Part B payment limit
CMS publishes a quarterly payment limit for the HCPCS codes that its NDC crosswalk links to Novolog. It is a ceiling for providers who bill Medicare Part B, not a price a patient pays, and a code's presence says nothing about whether Medicare covers a product.
| HCPCS code | Quarter | Payment limit | Per dosage descriptor | Effective | Read |
|---|---|---|---|---|---|
| J1811 | 2026 Q4 | $1.18 | 50 UNITS | October 1, 2026 through December 31, 2026 | November 7, 2026 |
| J1817 | 2026 Q4 | $3.12 | 50 UNITS | October 1, 2026 through December 31, 2026 | November 7, 2026 |
Source: CMS ASP pricing files (october-2026-medicare-part-b-payment-limit-files-final.zip and the matching NDC-HCPCS crosswalk). CMS ASP pricing files page.
Biosimilar status
- Novolog (insulin aspart) is a reference product in the FDA Purple Book (BLA 020986, approved June 7, 2000). The Purple Book lists 1 biosimilar and 2 interchangeable products that name it as their reference product.
Biosimilars: Merilog, approved February 14, 2025
Interchangeable: Kirsty, interchangeable since July 15, 2025; Garzulys, interchangeable since September 15, 2026 - Fiasp (insulin aspart) is a reference product in the FDA Purple Book (BLA 208751, approved September 29, 2017). The Purple Book lists 0 biosimilars and 0 interchangeable products that name it as their reference product.
This is what the FDA Purple Book lists on the read date. It is a record, not a forecast of when any product will launch or be substituted.
Source: FDA Purple Book (purplebook-2026-10), read November 7, 2026. Purple Book data file.
Medicaid use by state
CMS's State Drug Utilization Data records, for 2025, how many prescriptions each state's Medicaid program paid for under this drug's packages and what it reimbursed. The 10 states with the largest reimbursement are shown of 28 with data. Reimbursement is before the rebates manufacturers pay states, so it is not a net cost and not a price a patient pays.
| State | Medicaid-paid prescriptions | Medicaid reimbursed | Covers |
|---|---|---|---|
| NY | 1,008 | $866,224 | All record types |
| CA | 795 | $814,906 | Fee-for-service only |
| GA | 570 | $527,283 | All record types |
| CT | 175 | $257,291 | All record types |
| NH | 982 | $242,597 | Fee-for-service only |
| FL | 696 | $222,604 | All record types |
| ME | 250 | $202,769 | All record types |
| WI | 225 | $161,961 | All record types |
| IN | 236 | $155,111 | Fee-for-service only |
| PA | 328 | $144,484 | Fee-for-service only |
Where the publisher suppresses small managed-care cells, a state's figure covers fee-for-service claims only and understates use (15 state and package figures are marked that way here). A state missing from the table means its figures were suppressed or not reported, not zero use. 419 older-year figures are held and left out of the table.
Source: CMS State Drug Utilization Data (State Drug Utilization Data 2025, modified 2026-07-13T15:28:32Z), read November 7, 2026. CMS dataset page. State-reported data compiled by CMS; aggregate by state and package, no provider or patient data.
Where help paying exists
Programs in our finder that list insulin aspart, human. Each shows its income ceiling, when we read it and whether we checked it against the program's own document. Eligibility is decided by the program, not by us.
- Novo Nordisk Patient Assistance Program manufacturer
Income limit not stated: Novo Nordisk says only that household income must qualify (its page read 29 October 2026), so call 1-866-310-7549 to ask
Limit read October 29, 2026.Status. Novo Nordisk states that Medicare beneficiaries with prescription drug coverage will no longer be eligible to receive Ozempic through its Patient Assistance Program, and that some medicines will no longer be part of the program for 2026 (the page points to a separate list of the medicines that remain covered). (read November 7, 2026)
- Novo Nordisk Insulin Affordability Programs manufacturer
No income limit in our data
Figure not yet re-read on the program's own page.
Check where your income sits against each ceiling: open the assistance finder. See what has changed and when we last verified each program on the program status board.
Label changes
The FDA file lists no non-manufacturing label change for these applications since November 11, 2025. The most recent one it lists is dated June 21, 2023 (Labeling).
Source: FDA Drugs@FDA data file, read November 7, 2026. Dates are the FDA action dates; the documents are on FDA's own site. FDA data file. All recent changes across these drugs: label changes feed.
Safety notices
FDA enforcement report entries that name a package of Novolog by its NDC: 5 entries, newest first. FDA assigns each a class by health risk: Class I is the most serious and Class III the least. An entry records what the recalling firm reported and FDA classified; it is not advice about any package you hold.
| Reported | Class | Status | Recalling firm | Reason (shortened) | Packages named |
|---|---|---|---|---|---|
| April 21, 2021D-0611-2021 | Class I | Terminated | Novo Nordisk Inc | Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors. | 6 |
| April 21, 2021D-0612-2021 | Class I | Terminated | Novo Nordisk Inc | Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors. | 6 |
| April 21, 2021D-0613-2021 | Class I | Terminated | Novo Nordisk Inc | Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors. | 6 |
| April 21, 2021D-0615-2021 | Class I | Terminated | Novo Nordisk Inc | Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors. | 6 |
| April 21, 2021D-0616-2021 | Class I | Terminated | Novo Nordisk Inc | Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors. | 6 |
Source: openFDA drug enforcement reports, file read November 7, 2026. openFDA data file. All recent recalls across these drugs: drug recalls feed.
Clinical trials recruiting
ClinicalTrials.gov lists 8 interventional trials that name insulin aspart, human and are recruiting, and 6 more not yet recruiting. By phase: Phase 4: 3, Not applicable: 3, Early phase 1: 2. The 8 most recently updated are below. A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
| Trial | Title and conditions | Phase | Lead sponsor | Last updated | Countries |
|---|---|---|---|---|---|
| NCT06547619 | Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDMGestational Diabetes; Endothelial Dysfunction; Physical Inactivity | Early phase 1 | Anna Stanhewicz, PhD | October 29, 2026 | United States |
| NCT06445946 | DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational DiabetesGestational Diabetes Mellitus; Pregnancy, High Risk | Phase 4 | Ohio State University | October 7, 2026 | United States |
| NCT05946785 | Oxidative Stress in Microvascular Dysfunction Following Gestational DiabetesGestational Diabetes; Vascular Endothelial Function | Early phase 1 | Anna Stanhewicz, PhD | July 29, 2026 | United States |
| NCT03987308 | Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM PatientsType 2 Diabetic Patients; T2DM (Type 2 Diabetes Mellitus); T2DM | Not applicable | Beijing Hospital | May 2, 2025 | China |
| NCT06739473 | Total-body Glucose Utilization in ObesityObesity and Overweight | Phase 4 | Turku University Hospital | December 18, 2024 | Finland |
| NCT06532461 | A Trial of Three- and Seven-days Insulin Infusions SetType 1 Diabetes | Not applicable | Steno Diabetes Center Copenhagen | August 6, 2024 | Denmark |
| NCT05221359 | Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 DiabetesType 1 Diabetes; Type 1 Diabetes Mellitus With Hypoglycemia | Not applicable | Defymed | July 27, 2022 | France |
| NCT03463564 | Insulin Pump vs Multiple Daily Injections of Insulin and Glyco-metabolic Control in Type 1 Diabetic PatientsType 1 Diabetes Mellitus | Phase 4 | University of Campania Luigi Vanvitelli | March 15, 2018 | Italy |
Source: ClinicalTrials.gov, registry data processed November 6, 2026, summarized and trimmed by OmniRx. Search on ClinicalTrials.gov.
Questions
What is the Medicare negotiated price of Novolog?
For a 30-day supply the price CMS published is $119, in force since January 1, 2026. CMS's file lists all 17 packages of Novolog as deselected from the negotiation program, with the negotiated price ending December 31, 2026. After that date there is no negotiated price for them. The file does not say why. This is a price CMS agreed with the manufacturer for Medicare Part D, not what a person pays at the counter.
How does the negotiated price compare with what pharmacies pay?
Across the 7 packages where both CMS files give a price per unit, the median negotiated price is 100% of NADAC, the pharmacy acquisition benchmark (NADAC as of November 4, 2026). NADAC is a survey average, not a quote.
Is there help paying for Novolog?
2 assistance programs list it in our finder. Eligibility depends on income, coverage and the program's current rules; each program's own page decides.
Can I join a clinical trial for Novolog?
ClinicalTrials.gov lists 8 recruiting interventional trials that name insulin aspart, human (registry data processed November 6, 2026). A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
How much does Medicare Part D spend on Novolog?
CMS's Medicare Part D spending dataset reports gross spending on Novolog of $318.91 million in 2024, across 1,483,591 claims and 479,549 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
For developers: this drug as data
One call returns price, generic-entry upper bound, label history, recalls, trials, assistance, and where facts exist the FDA safety program (REMS), DEA schedule, orphan designations, safety notices and Medicaid use by state, each with receipts.
Example file: https://omnirx.org/api/v1/dossier/novolog.json
The licence page sets out what a data licence covers, and the API page documents these files.
Evaluation files with receipts; contract may change; not clinical advice.
Sources and terms. CMS Medicare Drug Price Negotiation Program data file (read November 6, 2026; the CMS page states no licence or restriction); CMS NADAC from data.medicaid.gov under the labels in the OmniRx licence ledger; program details read from each program's own pages; CMS Medicare Part D spending by drug; CMS ASP pricing files; FDA Purple Book; FDA Drugs@FDA and Orange Book data files; openFDA drug enforcement reports; ClinicalTrials.gov registry data. Figures are stored with their sources in the OmniRx library (edition 2026-11). Free to cite with attribution. Not medical, legal or financial advice. Report an error through the contact page. Licence the data.